Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERICA: Infliximab in Ulcerative Colitis
NCT01408810Phase 4Completed
- Sponsor
- Grupo de Estudo da Doença Inflamatória Intestinal
- Start
- Feb 2011
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in ulcerative colitis (UC), sponsored by Grupo de Estudo da Doença Inflamatória Intestinal. Primary endpoints: Histological remission at 8 weeks and Clinical response at 8 weeks. Started Feb 2011; status: completed.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01408810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01408810.